For its part, Hims & Hers maintains that the 'Sick of the System' ad – its first for a Super Bowl – "highlights the growing ...

The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...

Bain Capital Private Equity has proposed to acquire the remaining shares of surgical facility operator Surgery Partners it ...

Kenya Medical Training College, in partnership with UNHCR, has announced 50 Community Health Nursing scholarships for Turkana ...

Learn more about whether AbbVie Inc. or Genmab A/S is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Europe to review safety data for Eisai-Biogen Alzheimer's drug January 31, 2025 Veru said on Monday its experimental drug in combination with Novo ... to a research letter published on Friday.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity ...

Shares of Denmark’s Novo Nordisk (NOV: N) rose 3.5% to 613.30 kroner this morning ... data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily ...

While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic ...